The Svs3a Inhibitors chemical class represents a diverse array of compounds that indirectly target the Svs3a protein. This class is not unified by a single mode of action but instead encompasses various molecules that interact with different signaling pathways and cellular processes potentially related to Svs3a's activity. Key members of this class include kinase inhibitors like Lapatinib and Ruxolitinib, which target specific signaling cascades. The presence of such inhibitors highlights the potential cross-talk between Svs3a and various signal transduction pathways.
Metabolic modulators like Metformin also form an essential part of this class, suggesting that Svs3a activity might be connected to cellular metabolism and energy regulation. The inclusion of Bortezomib, a proteasome inhibitor, points to the relevance of protein degradation pathways in modulating Svs3a, whereas Canertinib's role as an epidermal growth factor receptor inhibitor suggests a link with cell growth and differentiation pathways.
Hormone-related modulators, such as Tamoxifen, emphasize the potential hormonal regulation of Svs3a, especially in hormone-sensitive tissues. The presence of Thalidomide, an immunomodulatory agent, and Ruxolitinib, a JAK inhibitor, indicates the potential involvement of Svs3a in immune response pathways.
Histone deacetylase inhibitors like Vorinostat and Trichostatin A are significant as they suggest epigenetic regulation mechanisms might be critical in controlling Svs3a activity. The role of Rapamycin, an mTOR inhibitor, underscores the importance of cellular growth pathways, whereas Zoledronic acid's presence highlights Svs3a's potential role in bone metabolism.
Together, these inhibitors represent a strategic approach towards understanding and potentially modulating Svs3a's function. They provide a broad spectrum of molecular interventions, each shedding light on different aspects of Svs3a's role within the cell. This chemical class is crucial for researchers aiming to unravel the complex biological functions of Svs3a and its interactions with various cellular pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
A dual tyrosine kinase inhibitor, potentially interfering with signaling pathways linked to Svs3a function. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
An AMPK activator, could modify metabolic pathways intersecting with Svs3a's regulatory mechanisms. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, may alter protein degradation pathways that affect Svs3a stability or function. | ||||||
Canertinib | 267243-28-7 | sc-207397 | 10 mg | $260.00 | 3 | |
An epidermal growth factor receptor inhibitor, possibly affecting signaling pathways related to Svs3a. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
A selective estrogen receptor modulator, might influence hormone-regulated pathways interacting with Svs3a. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
An immunomodulatory drug, could impact immune signaling pathways that intersect with Svs3a's role. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
A JAK inhibitor, may affect cytokine signaling pathways that could modulate Svs3a activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK, a kinase in the MAPK pathway, could indirectly influence Svs3a through this pathway. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
A histone deacetylase inhibitor, may affect chromatin remodeling processes related to Svs3a expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, could alter cellular growth and survival pathways that interact with Svs3a. | ||||||